SORBI, Claudia
 Distribuzione geografica
Continente #
NA - Nord America 7.848
EU - Europa 4.681
AS - Asia 3.486
SA - Sud America 557
AF - Africa 100
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 4
Totale 16.705
Nazione #
US - Stati Uniti d'America 7.680
IT - Italia 1.091
GB - Regno Unito 1.048
SG - Singapore 998
CN - Cina 856
SE - Svezia 644
DE - Germania 597
VN - Vietnam 455
HK - Hong Kong 438
BR - Brasile 423
FI - Finlandia 295
RU - Federazione Russa 229
FR - Francia 180
UA - Ucraina 125
BD - Bangladesh 116
KR - Corea 106
TR - Turchia 104
IN - India 103
CA - Canada 93
BE - Belgio 89
BG - Bulgaria 70
NL - Olanda 69
ID - Indonesia 55
IE - Irlanda 50
MX - Messico 44
AR - Argentina 40
JP - Giappone 40
PL - Polonia 35
RO - Romania 33
LT - Lituania 29
IQ - Iraq 27
EC - Ecuador 24
ES - Italia 23
IR - Iran 23
NZ - Nuova Zelanda 23
AT - Austria 21
ZA - Sudafrica 19
AE - Emirati Arabi Uniti 18
CO - Colombia 18
TW - Taiwan 18
CL - Cile 17
EG - Egitto 17
IL - Israele 17
VE - Venezuela 15
PK - Pakistan 13
NO - Norvegia 11
CH - Svizzera 10
KE - Kenya 10
KZ - Kazakistan 10
MA - Marocco 10
TH - Thailandia 10
MY - Malesia 9
SA - Arabia Saudita 9
PH - Filippine 8
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
DZ - Algeria 7
NG - Nigeria 7
TN - Tunisia 7
AU - Australia 6
AZ - Azerbaigian 6
CI - Costa d'Avorio 6
JO - Giordania 6
NI - Nicaragua 6
NP - Nepal 6
JM - Giamaica 5
PE - Perù 5
PY - Paraguay 5
UY - Uruguay 5
BO - Bolivia 4
BY - Bielorussia 4
CR - Costa Rica 4
EU - Europa 4
HN - Honduras 4
LB - Libano 4
SN - Senegal 4
AL - Albania 3
BH - Bahrain 3
DK - Danimarca 3
ET - Etiopia 3
LU - Lussemburgo 3
PR - Porto Rico 3
PS - Palestinian Territory 3
UG - Uganda 3
DO - Repubblica Dominicana 2
EE - Estonia 2
HU - Ungheria 2
MM - Myanmar 2
OM - Oman 2
RS - Serbia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TG - Togo 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
Totale 16.684
Città #
Ashburn 669
Santa Clara 652
Southend 644
Singapore 613
Fairfield 519
Hong Kong 416
Chandler 389
Woodbridge 353
San Jose 346
Ann Arbor 329
Munich 324
Chicago 301
Nyköping 280
Houston 275
Seattle 258
Hefei 252
New York 235
Jacksonville 224
Helsinki 217
Beijing 204
Wilmington 191
Dearborn 189
Cambridge 187
Modena 181
Los Angeles 170
Council Bluffs 148
London 146
Ho Chi Minh City 143
Hanoi 103
Seoul 89
Brussels 88
Salt Lake City 83
The Dalles 78
Milan 70
Sofia 66
San Diego 62
Eugene 53
Princeton 53
Elk Grove Village 52
Lauterbourg 48
Dublin 47
Izmir 46
Orem 45
São Paulo 43
Moscow 40
Tampa 40
Buffalo 38
Bologna 37
Tokyo 37
Amsterdam 35
Toronto 35
Dallas 34
Fremont 34
Jakarta 33
Da Nang 32
Rome 31
Redwood City 28
Shanghai 28
Boardman 25
Bremen 25
Frankfurt am Main 25
Warsaw 25
Mexico City 24
Auckland 23
Turku 23
Sochi 22
Sterling 20
Yalova 20
Brooklyn 19
Phoenix 18
Augusta 17
Norwalk 17
Haiphong 16
Mumbai 16
Parma 16
Philadelphia 16
Reggio Emilia 16
Grafing 15
Jyväskylä 15
Montreal 15
Atlanta 14
Denver 14
Guangzhou 14
Boston 13
Chennai 13
Des Moines 13
Lancaster 13
San Francisco 13
Stockholm 13
Baghdad 12
Hillsboro 12
Horia 12
Leawood 12
Manchester 12
Naples 12
Paris 12
Zanjan 12
Columbus 11
Falkenstein 11
Guayaquil 11
Totale 11.040
Nome #
1,3-Dioxolane-Based Ligands Incorporating a Lactam or Imide moiety: Structure-Affinity/Activity Relationship at alpha1–Adrenoceptor subtypes and at 5-HT1A Receptors 750
(2,2-difenil-[1,3]-diossolan-4ilmetil)-(3-fenil-propil)-ammina: nuovo agonista parziale del recettore serotoninergico 5-HT1A 643
1,3-Dioxane as a scaffold for potent and selective 5-HT1AR agonist with in-vivo anxiolytic, anti-depressant and anti-nociceptive activity 573
1,3-Dioxolane-Based Ligands as a Novel Class of Alpha1-Adrenoceptor Antagonists 526
1,3-Dioxolane-Based Ligands as Rigid Analogues ofNaftopidil: Structure–Affinity/Activity Relationships at a1and 5-HT1A Receptors 497
1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands 452
1,3-dioxolane-based ligands in the search for alpha1-adrenergic antagonists. 449
(2,2-Diphenyl-[1,3]oxathiolan-5-ylmethyl)-(3-phenylpropyl)-amine: a Potent and Selective 5-HT1A Receptor Agonist 446
Enantiomeric resolution of [(2,2-diphenyl-1,3-dioxolan-4-yl)methyl](2-phenoxyethyl)amine, a potent α1and 5-HT1Areceptor ligand: an in vitro and computational study 445
Discovery of a new 5-HT1A receptor agonist, acting ‘in vivo’ in a rat model of anxiety and depression 428
A New and Versatile Synthesis of 1,3-Dioxan-5-yl-pyrimidine and Purine Nucleoside Analogues 393
A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists 374
Discovery Of New Sigma-2 Receptor Agonist Endowed With Antiproliferative Activity 366
Synthesis, biological evaluation and molecular modeling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT1A receptor agonists 348
Structure-Activity Relationship within a new series of σ1 and σ2 receptor ligands: identification of a novel σ2R agonist (BS148) with selective toxicity against metastatic melanoma 338
Diastereoselective Synthesis of (1,3-Dioxan-4-yl)pyrimidine and Purin Nucleoside Analogues 338
Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-HT1A receptors 335
Synthesis and structure-activity relationships of 1-aralkyl-4- benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent σ ligands 330
Discovery of a new series of 5-HT1A receptor agonists 329
Synthesis of 6-O-methotrexylhyaluronan as a drug delivery system 329
Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs) 305
Synthesis and biological evaluation of 1,3-dioxolane-based 5-HT 1A receptor agonists for CNS disorders and neuropathic pain 304
Scouting Sigma Receptor Ligands As New Tools For The Treatment Of Neurodegenerative Diseases And Cancer 302
DAT atypical inhibitors as novel antipsychotic drugs 297
Synthesis, structural characterization and biological evaluation of 4′-C-methyl- and phenyl-dioxolane pyrimidine and purine nucleosides 293
BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting 288
Synthesis, biological evaluation and molecular modelling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT1A receptor agonists 274
Exhaustive CoMFA and CoMSIA analyses around different chemical entities: A ligand-based study exploring the affinity and selectivity profiles of 5-HT1A ligands 270
Structure-activity relationship at alpha-adrenergic receptors within a series of imidazoline analogues of cirazoline 269
Transacetalization of Acetals with Butane-1,2,4-triol Using Cobalt(II) Chloride and Chlorotrimethylsilane 268
Synthesis and Structure-Activity Relationships of Triazaspirodecanone Derivatives as Nociceptin/Orphanin FQ Receptor Ligands 263
Synthesis of 5-Methyl-1,3-oxathiolane-based Nucleoside Analogues as Potential Antiviral Agents 258
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer 250
Structure Activity Relationships at 5-HT1A receptors within a novel series of 4-alkyl-1-arylpiperazine derivatives 244
Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents 244
Pyrrolidine Derivatives as New Ligands for 5-HT1A Receptors 243
Effect of the rigidification of propranolol, a mixed β-adrenoceptor and 5-HT1AR antagonist 236
Identification of a Potent and Selective 5-HT1AReceptor Agonist with In Vitro and In Vivo Antinociceptive Activity 236
Synthesis, enantiomeric separation and docking studies of spiropiperidine analogues as ligands of the nociceptin/orphanin FQ receptor 232
Synthesis, absolute configuration and antimuscarinic activity of the enantiomers of [1-(2,2-diphenyl-[1,3]dioxolan-4-yl)-ethyl]dimethyl-amine 227
Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group 220
Constrained 1,4-dialkylpiperazines as monoamine transporters inhibitors for cocaine-related abuse 215
Synthesis, structural characterization and pharmacological evaluation of spiroxatrine analogs as potential nociceptin/orphanin FQ receptor ligands 202
Derivati 1,3-Diossanici come Antagonisti Muscarinici 200
Effect of the replacement of the o-methoxyphenyl moiety with nitrogen-containing aromatic rings within N-phenyl-piperazine and phenoxy-ethylamine-based 1,3-dioxo/oxathio/dithiolanes as α1 and 5-HT1A receptor ligands 198
Novel S1R agonists counteracting NMDA excitotoxicity and oxidative stress: A step forward in the discovery of neuroprotective agents 198
1,3-Dithiolane as a Privileged Scaffold in Bioactive Derivatives: Chiral Resolution and Assignment of Absolute Configuration 196
Spiroxatrine derivatives towards 5-HT1A receptor selectivity 187
Relazioni struttura-attività in una nuova serie di ligandi alpha1-adrenergici e 5-HT1A serotoninergici a struttura 2,2-difenil-[1,3]diossolanica 186
Synthesis and structural characterization of spiroxatrine derivatives as potential non-peptide ligands for NOP receptor 184
IDENTIFICATION OF POTENT 1,3-DIOXOLANE-BASED 5-HT1A RECEPTOR AGONISTS FOR THE TREATMENTS OF CNS DISORDERS AND PAIN 184
Synthesis and pharmacological evaluation of Spiroxatrine derivatives as potential ligands for NOP receptor 177
Nuova Serie di Ligandi Sigma a Struttura Piperazinica e Piperidinica 174
Structure-Activity Relationships at alpha1-Adrenoceptor Subtypes within a New Series of 1,3-Dioxolane Derivatives 143
Insights into the Structural Conformations of the Tau Protein in Different Aggregation Status 117
Farmaci attivi sul sistema nervoso adrenergico 86
Structure-Based Discovery of Hsp90/HDAC6 Dual Inhibitors Targeting Aggressive Prostate Cancer 16
Totale 16.875
Categoria #
all - tutte 58.945
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.945


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.192 64 106 77 90 49 95 38 65 175 86 206 141
2022/20231.406 221 168 114 151 147 163 42 107 163 46 59 25
2023/2024948 20 51 99 103 216 86 58 126 9 38 69 73
2024/20253.210 161 41 72 163 487 443 422 268 308 148 295 402
2025/20265.442 345 200 434 772 1.058 333 644 278 466 405 271 236
2026/202726 26 0 0 0 0 0 0 0 0 0 0 0
Totale 16.875